Home›Trial›NCT07215390
NCT07215390Phase 2RECRUITING

A Phase 2, Randomized, Placebo Controlled, Multicenter, Masked Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacodynamics of Multidose APL 3007 in Combination With Syfovre/Pegcetacoplan (APL-2) in Patients Diagnosed With Geographic Atrophy Secondary to Age Related Macular Degeneratio

Study Summary

A Phase 2, Randomized, Placebo-controlled, Multicenter, Masked Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacodynamics of Multidose APL-3007 in Combination with Syfovre/Pegcetacoplan (APL-2) in Patients Diagnosed with Geographic Atrophy Secondary to Age-Related Macular Degeneration

Conditions
Geographic Atrophy Secondary to Age-related Macular Degeneration
Interventions / Drugs
APL-3007, pegcetacoplan (APL-2)APL-3007, pegcetacoplan (APL-2)Placebo, Syfovre
View on ClinicalTrials.gov ↗
Sponsor
APLS
Apellis Pharmaceuticals
Complement Inhibitors
D37/100
Study Details
Enrollment240 participants
Primary Completion—
Lead SponsorApellis Pharmaceuticals, Inc.
Data Retrieved2026-04-11 02:54:08.046067+00:00
What This Trial Means for Biotech Investors
Trial Phase Context

Phase 2 trials begin testing efficacy in a larger patient group (100–300). This is often where biotech binary events occur — positive Phase 2 data can significantly advance a company's pipeline narrative, while failures can be terminal for a program.

Status & Expected Data

Currently recruiting: the trial is enrolling patients. A data readout is not expected until after enrollment closes and the follow-up period is complete.

Enrolled: 240 participants
Sponsor Catalyst Profile

Apellis Pharmaceuticals (APLS) is the sponsoring company for this trial. BiotechSign currently grades this company D (37/100) based on composite catalyst signals across its full pipeline. This trial is one data point in that overall catalyst picture.

APLS Full Pipeline →All Companies →
Not financial advice. BiotechSign data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.